Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May-Jun;28(3):308-13.
doi: 10.1016/j.urolonc.2008.09.022. Epub 2008 Dec 12.

Disparities in the treatment of patients with IL-2 for metastatic renal cell carcinoma

Christopher S Saigal  1 , Christopher M Deibert, Julie Lai, Matthias Schonlau
Affiliations

Disparities in the treatment of patients with IL-2 for metastatic renal cell carcinoma

Christopher S Saigal et al. Urol Oncol. 2010 May-Jun.

Abstract

Objectives: The incidence of metastatic renal cell cancer (mRCC) is rising. To date, interleukin-2 (IL-2) is the only treatment offering a complete response rate for mRCC. We wish to test the hypothesis that the combination of restricted availability and expense associated with IL-2 administration results in differential access to the medication based on race and sex, despite similar clinical indications for its use.

Methods: We used data from the Surveillance, Epidemiology, and End Results program and the Centers for Medicare Services (CMS) to clinically characterize subjects with mRCC diagnosed from 1992 through 2002. We linked these subjects to claims identified in the CMS databases. We then assigned subjects to cohorts receiving radical nephrectomy, IL-2, both, or neither. A logistic model was created to identify factors that had significant independent effects on the receipt of IL-2.

Results: Three thousand seven hundred thirty individuals were identified with mRCC. After controlling for other variables, female subjects were less likely to receive IL-2 (O.R. 0.80). African American subjects were also less likely to receive IL-2 (O.R 0.55). Married individuals were much more likely to receive IL-2 (O.R 1.9).

Conclusions: African Americans and women were much less likely to be treated with IL-2 after controlling for relevant clinical variables. These data document that the only therapy offering a complete response to patients with mRCC is less frequently given to those who are African American or female. It is possible that the racial and gender-based disparities in treatment with IL-2 will be replicated with newer, expensive treatment options for mRCC. Further prospective investigation into mitigating barriers to receipt of effective care for mRCC is urgently needed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival associated with different therapies for metastatic kidney cancer
See this image and copyright information in PMC

References

    1. Chow WH, Devesa SS, Warren JL, Fraumeni JF., Jr Rising incidence of renal cell cancer in the United States. Jama. 1999;281(17):1628–1631. - PubMed
    1. Bretheau D, Lechevallier E, Eghazarian C, Grisoni V, Coulange C. Prognostic significance of incidental renal cell carcinoma. Eur Urol. 1995;27(4):319–323. - PubMed
    1. Homma Y, Kawabe K, Kitamura T, Nishimura Y, Shinohara M, Kondo Y, Saito I, Minowada S, Asakage Y. Increased incidental detection and reduced mortality in renal cancer--recent retrospective analysis at eight institutions. Int J Urol. 1995;2(2):77–80. - PubMed
    1. Jayson M, Sanders H. Increased incidence of serendipitously discovered renal cell carcinoma. Urology. 1998;51(2):203–205. - PubMed
    1. Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM, Rosenberg S. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008;113(2):293–301. - PMC - PubMed